Mason, W.P.

patient radiotherapy tumor treatment glioblastoma temozolomide survival group trial study cancer analysis recurrence glioma prognostic oncol gbm-o pattern eortc bene fit fication research oligodendroglioma-like component university brain baseline number mutation month status outcome signi table phase location value methylation factor lesion promoter component review feature neuropathol progression necrosis effect department adjuvant temozolomide idh 1 mutations analyses 5 years class chemotherapy presence follow-up tumor locations frequency subtype glioblastoma multiforme cancer institute mgmt methylation status canada therapy diagnosis classi fication adjuvant pathology classi radiotherapy group van den tumour european organisation survival group surgery signi ficantly centre 1·0 lausanne university hospital lausanne